financetom
Business
financetom
/
Business
/
Goldman Sachs urged to separate CEO and chair roles by proxy advisers
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Goldman Sachs urged to separate CEO and chair roles by proxy advisers
Apr 4, 2024 8:41 AM

April 4 (Reuters) -

Goldman Sachs ( GS ) should separate the CEO and chairman

roles currently held by David Solomon, proxy adviser Glass Lewis

wrote in a report on Thursday.

The recommendation to shareholders followed a similar

suggestion from Institutional Shareholder Services on Wednesday.

Glass Lewis said having an independent chair "is nearly

always preferable to having a single individual lead both the

board and the executive team."

In addition, it recommended investors cast advisory

votes against compensation at the Wall Street bank.

Goldman shareholders "should be wary of the continued

disconnect between pay and performance," Glass Lewis wrote in

its report, saying the pay for Solomon and other top executives

together was above the median of peers used its model.

ISS' comments on Solomon's leadership on Wednesday made

specific mention of the bank's strategy.

"Solomon's foray into the consumer realm has been met

with missteps and steep losses, which seem to have trickled into

further human capital issues," it wrote in the report on

Wednesday.

Goldman Sachs ( GS ) did not immediately provide a comment. On

Wednesday, a company spokesperson cited the bank's

recommendation to vote against the independent chair proposal as

laid out in its proxy statement.

The resolution to split Goldman's chairman and CEO

titles was filed by the National Legal and Policy Center. A

similar measure it filed last year won just 16% support.

Last year, Glass Lewis had also recommended investors

vote for the separation of the chairman and CEO roles as a

matter of good corporate governance. Meanwhile, ISS had

recommended against the measure, saying at the time there were

"no significant concerns regarding the company's governance

practices."

Goldman's annual meeting is slated for April 24. Like

ISS, Glass Lewis recommended votes approving all the bank's

director nominees, including Solomon.

The bank appointed David Viniar, who served as its

finance chief from 1999 to 2013, as its next independent lead

director. He will succeed Adebayo Ogunlesi, who will step down

at the annual meeting.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Ex-Barclays CEO Staley insists he was 'shocked' by Epstein's arrest
Ex-Barclays CEO Staley insists he was 'shocked' by Epstein's arrest
Mar 11, 2025
* Ex-Barclays ( JJCTF ) boss says he had no knowledge of Epstein's crimes * Staley facing finance industry ban, $2.3 million fine * FCA says Staley approved misleading letter about relationship (Recasts with later evidence, adds details in paragraphs 4-8, 14-17) By Sam Tobin LONDON, March 11 (Reuters) - Ex-Barclays boss Jes Staley on Tuesday insisted he was shocked...
Medical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 Million
Medical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 Million
Mar 11, 2025
On Tuesday, Bioventus Inc ( BVS ). reported fourth-quarter adjusted EPS of 15 cents, up from 7 cents, beating the consensus of 8 cents. The medical device company reported sales of $153.6 million, up 13.5% year over year, beating the consensus of $145.2 million, driven by double-digit growth in pain treatments and surgical solutions. Pain treatment sales increased 18.7% to...
--Boeing Delivers 44 Aircraft in February Compared With 45 in January
--Boeing Delivers 44 Aircraft in February Compared With 45 in January
Mar 11, 2025
11:16 AM EDT, 03/11/2025 (MT Newswires) -- Price: 147.42, Change: -0.74, Percent Change: -0.50 ...
What's Going On With Sonoma Pharmaceuticals Stock Tuesday?
What's Going On With Sonoma Pharmaceuticals Stock Tuesday?
Mar 11, 2025
Sonoma Pharmaceuticals, Inc. ( SNOA ) stock is trading higher on Tuesday after the company announced that it secured U.K. regulatory clearance for its key wound care and dermatology products. The Details: Sonoma received clearance from the Medicines & Healthcare products Regulatory Agency for five products, including its hypochlorous acid-based wound irrigation solution, scar management products, wound hydrogel and skin...
Copyright 2023-2026 - www.financetom.com All Rights Reserved